Literature DB >> 14691385

The TWEAK is weak for alcohol screening among female Veterans Affairs outpatients.

Kristen R Bush1, Daniel R Kivlahan, Tania M Davis, Dorcas J Dobie, Jennifer L Sporleder, Amee J Epler, Katharine A Bradley.   

Abstract

BACKGROUND: The optimal brief questionnaire for alcohol screening among female patients has not yet been identified. This study compared the performance of the TWEAK (tolerance, worried, eye-opener, amnesia, cutdown), the Alcohol Use Disorders Identification Test (AUDIT), and the AUDIT Consumption (AUDIT-C) as self-administered screening tests for hazardous drinking and/or active alcohol abuse or dependence among female Veterans Affairs (VA) outpatients.
METHODS: Women were included in the study if they received care at VA Puget Sound and completed both a self-administered survey containing the AUDIT and TWEAK screening questionnaires and subsequent in-person interviews with the Alcohol Use Disorders and Associated Disabilities Interview Schedule. Sensitivities, specificities, positive and negative likelihood ratios, and areas under Receiver Operating Characteristic curves were computed for each screening questionnaire compared with two interview-based comparison standards: (1) active DSM-IV alcohol abuse or dependence and (2) hazardous drinking and/or active DSM-IV alcohol abuse or dependence, the more appropriate target for primary care screening.
RESULTS: Of 393 women who completed screening questionnaires and interviews, 39 (9.9%) met diagnostic criteria for alcohol abuse or dependence, and 89 (22.7%) met criteria for hazardous drinking or alcohol abuse or dependence. The TWEAK had relatively low sensitivities (0.62 and 0.44) but adequate specificities (0.86 and 0.89) for both interview-based comparison standards, even at its lowest cut-point (>/=1). The AUDIT and AUDIT-C were superior, with the following areas under the receiver operating characteristic curve for active alcohol abuse or dependence and hazardous drinking and/or active alcohol abuse or dependence, respectively: AUDIT, 0.90 [95% confidence interval (CI), 0.85-0.95] and 0.87 (95% CI, 0.84-0.91); AUDIT-C, 0.91 (95% CI, 0.88-0.95) and 0.91 (95% CI, 0.88-0.94); and TWEAK, 0.76 (95% CI, 0.66-0.86) and 0.67 (95% CI, 0.60-0.74).
CONCLUSIONS: The TWEAK has low sensitivity as an alcohol-screening questionnaire among female VA outpatients and should be evaluated further before being used in other female primary care populations. The three-item AUDIT-C was the optimal brief alcohol-screening questionnaire in this study.

Entities:  

Mesh:

Year:  2003        PMID: 14691385     DOI: 10.1097/01.ALC.0000099262.50094.98

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  5 in total

1.  Posttraumatic stress disorder screening status is associated with increased VA medical and surgical utilization in women.

Authors:  Dorcas J Dobie; Charles Maynard; Daniel R Kivlahan; Kay M Johnson; Tracy Simpson; Andrew C David; Katharine Bradley
Journal:  J Gen Intern Med       Date:  2006-03       Impact factor: 5.128

Review 2.  The state of women veterans' health research. Results of a systematic literature review.

Authors:  Caroline L Goldzweig; Talene M Balekian; Cony Rolón; Elizabeth M Yano; Paul G Shekelle
Journal:  J Gen Intern Med       Date:  2006-03       Impact factor: 5.128

3.  Psychometric properties of alcohol screening tests in the emergency department in Argentina, Mexico and the United States.

Authors:  Mariana Cremonte; Rubén Daniel Ledesma; Cheryl J Cherpitel; Guilherme Borges
Journal:  Addict Behav       Date:  2010-04-10       Impact factor: 3.913

4.  Screening for alcohol problems among 4-year colleges and universities.

Authors:  Ken C Winters; Traci Toomey; Toben F Nelson; Darin Erickson; Kathleen Lenk; Mark Miazga
Journal:  J Am Coll Health       Date:  2011

5.  Harm reduction text messages delivered during alcohol drinking: feasibility study protocol.

Authors:  Karen Adell Renner
Journal:  JMIR Res Protoc       Date:  2012-05-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.